1. Partner presentation

2. Partner 1 – Karolinska Institutet Ulrik Ringborg WP15 Ethical issues – WP leader Rolf Lewensohn KI WP16 Management – WP leader Ulrik Ringborg KI

3. Partner 2 – Institut Curie Sergio Roman-Roman Participating in: WP3 Early detection WP4 Kinome analysis WP6 Therapeutic strategies WP8 Technological structures & resources for discovery WP10 Biobanking WP11 Epidemiology

4. Partner 3 – Danish Cancer Society Julio E. Celis WP1 Scientific coordination – WP leader J. E. Celis Participating partners: – DCS – INT – IGR – NKI – ERASMUS MC – UCAM – ECPC

5. Partner 4 – Oslo University Hospital, Radiumhospitalet Anne-Lise Børresen-Dale WP3 Early detection – WP leader A-L. Børresen-Dale together with INT Participating partners: - KI- Inst Curie - DCS- OUS - INT- DKFZ - IGR- IARC - UOXF.HD- IEO - CHRIS- NIO - NKI- UCAM - IJB- LUMC

6. Partner 5 – Spanish National Cancer Research Centre Mariano Barbacid WP7 Mouse models – WP leader M. Barbacid Participating partners: - CNIO - NKI - UCAM

7. Partner 6 – Fondazione IRCCS Istituto Nazionale dei Tumori Marco A. Pierotti WP3 Early detection – WP leader M. A. Pierotti together with OUS Participating partners: - KI- Inst Curie -DCS- OUS - INT- DKFZ - IGR- IARC - UOXF.HD- IEO - CHRIS- NIO - NKI- UCAM - IJB- LUMC

8. Partner 7 – German Cancer Research Centre Otmar D. Wiestler WP11 Epidemiology – WP-leaders Hermann Brenner & Cornelia Ulrich Participating partners: - KI- Inst Curie - DCS- OUS - INT- DKFZ - IARC- IEO - CHRIS- NKI - UCAM- ERASMUS MC - IJB

9. Partner 8 – Institut Gustave Roussy Alexander M. M. Eggermont WP6 Therapeutic strategies – WP-leader Thomas Tursz Participating partners: KI, Inst Curie, DCS, OUS, CNIO, INT, DKFZ, IGR, UOXF.HD, IEO, CHRIS, NIO, NKI, ERASMUS MC, UCAM, IJB, VHIO, EORTC WP12 Quality assurance/designation – WP-leader Mahasti Saghatchian together with NKI Participating partners: IGR, IEO, NKI, OECI

10. Partner 9 – International Agency for Research on Cancer Christopher Wild WP2 Prevention – WP leader C. Wild Participating partners: IGR, IEO, NKI, OECI

11. Partner 10 – Oxford Cancer Centre Nicholas La Thangue Participating in: WP3 Early detection WP6 Therapeutic strategies WP8 Technological structures & resources for discovery

12. Partner 11 – Istituto Europeo di Oncologia Umberto Veronesi Participating in: WP2 Prevention WP3 Early detection WP6 Therapeutic strategies WP8 Technological structures & resources for discovery WP10 Biobanking WP11 Epidemiology WP12 Quality assurance/designation

13. Partner 12 – Christie Foundation Trust Nicholas Jones Participating in: WP2 Prevention WP3 Early detection WP6 Therapeutic strategies WP10 Biobanking WP11 Epidemiology

14. Partner 13 – National Institute of Oncology Miklós Kasler Participating in: WP3 Early detection WP6 Therapeutic strategies WP8 Technological structures and resources for discovery WP10 Biobanking

15. Partner 14 - Netherlands Cancer Institute Anton Berns WP4 Kinome analysis – WP leader René Bernards Participating partners: IGR, IEO, NKI, OECI WP8 Technological structures & resources for discovery – WP leader René Bernards, Participating partners: KI, Inst Curie, DCS, OUS, CNIO, INT, DKFZ, IGR, UOXF.HD, IEO, NIO, NKI, EMC, UCAM WP12 Quality assurance/designation – WP leader Wim van Harten together with IGR Participating partners: IGR, IEO, NKI, OECI

16. Partner 15 – Erasmus University Medical Centre Rotterdam Alexander M.M. Eggermont WP10 Biobanking – WP leader Peter Riegman Participating partners: - KI - Inst Curie - OUS - CNIO - INT - IARC - IEO- CHRIS - NIO- NKI - EMC - UCAM - FIVO- OECI

17. Partner 16 – University of Cambridge, Dept of Oncology Carlos Caldas Participating in: WP3 Early detection WP4 Kinome analysis WP6 Therapeutic strategies WP7 Mouse models WP8 Technological structures & resources for discovery WP10 Biobanking WP11 Epidemiology

18. Partner 17 – Institut Jules Bordet Dominique de Valeriola Participating in: WP3 Early detection WP6 Therapeutic strategies WP11 Epidemiology

19. Partner 18 – European Molecular Biology Laboratory Jan Korbel WP9 Bioinformatics – WP leader Jan Korbel Participating partners: - KI - IGR - EMC - EMBL

20. Partner 19 – The Institute of Cancer Research Alan Ashworth Participating in: WP5 Targeting the DNA damage response

21. Partner 20 – Leiden University Medical Centre Nelleke Gruis Participating in: WP2 Prevention WP3 Early detection

22. Partner 21 – Fundacíon Institutio Valencian de Oncologia Antonio Llombart Bosch Participating in: WP10 Biobanking

23. Partner 22 – Istituto Tumori ”Giovanni Paolo II” Angelo Paradiso WP13 Education – WP leader Angelo Paradiso Participating partners: - NCI Bari - ECCO - OECI

24. Partner 23 – Vall d´Hebron Insitute of Oncology José Baselga Participating in: WP6 Therapeutic strategies

25. Partner 24 – eCancer Gordon McVie WP14 Communication and dissemination – WP leader Gordon McVie Participating partners: - ECMS - ECCO - OECI - ECPC

26. Partner 25 – European CanCer Organisation Michel Ballieu Participating in: WP1 Scientific coordination, oncopolicy WP13 Education WP14 Communication and dissemination

27. Partner 26 – Organisation of the European Cancer Institutes Marco A. Pierotti & Claudio Lombardo Participating in : WP10 Biobanking WP12 Quality assessment, accreditation and metrics WP13 Education WP14 Communication and dissemination

28. Partner 27 – European Cancer Patient Coalition Tom Hudson & Denis Horgan Participating in: WP1 Scientific coordination WP14 Communication & dissemination

29. Partner 28 – European Organisation of Research & Treatment of Cancer Françoise Meunier Participating in: WP1 Scientific Coordination WP6 Therapeutic Strategies WP10 Biobanking